Serum LAMC2 enhances the prognostic value of a multi-parametric panel in non-small cell lung cancer.

ABSTRACT:

Background

Non-small cell lung cancer (NSCLC) lacks reliable serological biomarkers for predicting patients' survival and response to treatment. The present study examined the capability of serum LAMC2 and four known tumour markers for disease prognosis and patients' risk stratification.

Methods

LAMC2, CA 125, CEA, CYFRA 21-1 and SCC levels were retrospectively measured in sera obtained from 127 patients diagnosed with NSCLC by commercial immunoassays. Prognostic performance of the markers was compared with established clinical parameters and multivariate models were constructed to assess the prognostic complementarity of variables.

Results

LAMC2 showed significant prognostic ability for overall survival (hazards ratio: 1.607, 95% confidence interval: 1.268-2.037, P<0

SUBMITTER: Korbakis D 

PROVIDER: S-EPMC4522621 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature